Camurus AB (publ) (CAMX.ST)
SEK 568.0
(1.07%)
SEK 568.0
(1.07%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 431.44 Million SEK | 676.63% |
| 2022 | 55.55 Million SEK | 161.42% |
| 2021 | -90.44 Million SEK | 45.93% |
| 2020 | -167.26 Million SEK | 42.3% |
| 2019 | -289.86 Million SEK | -23.52% |
| 2018 | -234.67 Million SEK | -23.14% |
| 2017 | -190.57 Million SEK | -135.3% |
| 2016 | -80.99 Million SEK | 49.23% |
| 2015 | -159.54 Million SEK | -430.0% |
| 2014 | 48.34 Million SEK | -51.28% |
| 2013 | 99.23 Million SEK | 645.18% |
| 2012 | 13.31 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 77.86 Million SEK | 612.06% |
| 2024 Q2 | 74.2 Million SEK | -4.71% |
| 2023 Q3 | 86.39 Million SEK | -71.34% |
| 2023 Q1 | 58.82 Million SEK | 350.21% |
| 2023 FY | 431.44 Million SEK | 676.63% |
| 2023 Q4 | -15.2 Million SEK | -117.6% |
| 2023 Q2 | 301.42 Million SEK | 412.37% |
| 2022 Q4 | 13.06 Million SEK | -62.66% |
| 2022 Q1 | -752 Thousand SEK | 94.63% |
| 2022 Q2 | 8.23 Million SEK | 1195.61% |
| 2022 Q3 | 34.99 Million SEK | 324.8% |
| 2022 FY | 55.55 Million SEK | 161.42% |
| 2021 Q4 | -14.01 Million SEK | -127.27% |
| 2021 Q2 | -48.38 Million SEK | -121.22% |
| 2021 Q1 | -21.87 Million SEK | 66.59% |
| 2021 FY | -90.44 Million SEK | 45.93% |
| 2021 Q3 | -6.16 Million SEK | 87.26% |
| 2020 Q3 | -20.28 Million SEK | -1.62% |
| 2020 Q4 | -65.47 Million SEK | -222.78% |
| 2020 FY | -167.26 Million SEK | 42.3% |
| 2020 Q1 | -61.55 Million SEK | 14.34% |
| 2020 Q2 | -19.96 Million SEK | 67.57% |
| 2019 Q1 | -67.62 Million SEK | 22.4% |
| 2019 Q3 | -62.73 Million SEK | 28.42% |
| 2019 FY | -289.86 Million SEK | -23.52% |
| 2019 Q2 | -87.64 Million SEK | -29.6% |
| 2019 Q4 | -71.85 Million SEK | -14.53% |
| 2018 Q4 | -87.14 Million SEK | -99.18% |
| 2018 FY | -234.67 Million SEK | -23.14% |
| 2018 Q3 | -43.75 Million SEK | 35.19% |
| 2018 Q2 | -67.5 Million SEK | -86.13% |
| 2018 Q1 | -36.26 Million SEK | 30.51% |
| 2017 FY | -190.57 Million SEK | -135.3% |
| 2017 Q4 | -52.19 Million SEK | 0.28% |
| 2017 Q3 | -52.33 Million SEK | -14.26% |
| 2017 Q2 | -45.8 Million SEK | -13.8% |
| 2017 Q1 | -40.24 Million SEK | -44.73% |
| 2016 Q2 | -20.55 Million SEK | -5.85% |
| 2016 Q3 | -13.21 Million SEK | 35.7% |
| 2016 Q4 | -27.8 Million SEK | -110.43% |
| 2016 FY | -80.99 Million SEK | 49.23% |
| 2016 Q1 | -19.41 Million SEK | 39.04% |
| 2015 Q1 | 10.21 Million SEK | -86.35% |
| 2015 Q2 | -115.17 Million SEK | -1227.24% |
| 2015 Q3 | -22.73 Million SEK | 80.26% |
| 2015 Q4 | -31.85 Million SEK | -40.07% |
| 2015 FY | -159.54 Million SEK | -430.0% |
| 2014 FY | 48.34 Million SEK | -51.28% |
| 2014 Q4 | 74.86 Million SEK | 4917.76% |
| 2014 Q3 | -1.55 Million SEK | 0.0% |
| 2013 FY | 99.23 Million SEK | 645.18% |
| 2012 FY | 13.31 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | 2717.973% |
| Amniotics AB (publ) | -30.87 Million SEK | 1497.609% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 3463.283% |
| BioArctic AB (publ) | 229.24 Million SEK | -88.198% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 192.547% |
| Saniona AB (publ) | -95.81 Million SEK | 550.31% |
| Simris Alg AB (publ) | -37.3 Million SEK | 1256.526% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 238.753% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 2145.621% |
| NextCell Pharma AB | -41.95 Million SEK | 1128.227% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 2731.068% |
| AcouSort AB (publ) | -17.08 Million SEK | 2624.677% |
| Active Biotech AB (publ) | -45.8 Million SEK | 1042.013% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 273.558% |
| Cantargia AB (publ) | -280.02 Million SEK | 254.072% |
| Genovis AB (publ.) | 61.5 Million SEK | -601.532% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 480.719% |
| Mendus AB (publ) | -101.61 Million SEK | 524.568% |
| Kancera AB (publ) | -64.88 Million SEK | 764.892% |
| Karolinska Development AB (publ) | 5.38 Million SEK | -7910.434% |
| LIDDS AB (publ) | -40.2 Million SEK | 1173.079% |
| Lipum AB (publ) | -37.17 Million SEK | 1260.477% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 3657.404% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | -3445.419% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 2510.695% |
| OncoZenge AB (publ) | -15.9 Million SEK | 2813.13% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 211.147% |
| Xintela AB (publ) | -54.08 Million SEK | 897.741% |
| Ziccum AB (publ) | -21.41 Million SEK | 2114.954% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 1263.826% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 340.134% |
| CombiGene AB (publ) | -35.66 Million SEK | 1309.693% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 384.124% |
| Intervacc AB (publ) | -102.85 Million SEK | 519.478% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | 98602.74% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 2711.16% |
| Corline Biomedical AB | -1.8 Million SEK | 23949.751% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 342.603% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 859.3% |
| Aptahem AB (publ) | -11.11 Million SEK | 3982.364% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 450.572% |
| Fluicell AB (publ) | -26.55 Million SEK | 1724.772% |
| Biovica International AB (publ) | -124.82 Million SEK | 445.643% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 1121.817% |
| Abliva AB (publ) | -95.5 Million SEK | 551.729% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 231.98% |
| 2cureX AB (publ) | -32.51 Million SEK | 1426.779% |
| I-Tech AB | 20.2 Million SEK | -2035.534% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 151.873% |
| Cyxone AB (publ) | -22.98 Million SEK | 1976.732% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 572.032% |
| Biosergen AB | -27.03 Million SEK | 1695.747% |
| Nanologica AB (publ) | -75.15 Million SEK | 674.054% |
| SynAct Pharma AB | -215.81 Million SEK | 299.918% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 1079.348% |
| BioInvent International AB (publ) | -330.3 Million SEK | 230.62% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 1917.593% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 273.193% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 4444.83% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 494.775% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 3794.485% |